LYMPHOCYTE BLAST TRANSFORMATION AND ANTIBODY RESPONSES AFTER VACCINATION WITH INACTIVATED MUMPS VIRUS VACCINE

2009 ◽  
Vol 89C (1-6) ◽  
pp. 303-310
Author(s):  
J. ILONEN ◽  
A. SALMI ◽  
K. PENTTINEN ◽  
E. HERVA
Keyword(s):  
Virus Vaccine ◽  
Mumps Virus ◽  
Antibody Responses ◽  
Blast Transformation ◽  
Lymphocyte Blast Transformation

EXPERIENCES WITH JERYL LYNN STRAIN LIVE ATTENUATED MUMPS VIRUS VACCINE IN A PEDIATRIC OUTPATIENT CLINIC

PEDIATRICS ◽  
1967 ◽  
Vol 40 (5) ◽  
pp. 798-803
Author(s):  
M. L. Young ◽  
B. Dickstein ◽  
R. E. Weibel ◽  
J. Stokes ◽  
E. B. Buynak ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Outpatient Clinic ◽  
Seroconversion Rate ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
Antibody Responses ◽  
Memorial Hospital ◽  
Controlled Study ◽  
Clinical Reaction ◽  
Pediatric Clinic

A controlled study of B level Jeryl Lynn strain live attenuated mumps virus vaccine was carried out during June through November 1966 in the pediatric outpatient clinic of the John F. Kennedy Memorial Hospital in Philadelphia. Altogether, 924 children were given the vaccine and paired sera were taken from a sample of 101 of the children for purpose of measuring initial serologic status for mumps and for ascertaining antibody responses. Based on the results obtained, it was estimated that roughly 410 of the children who were vaccinated were initially seronegative for mumps. Forty-eight of the 49 children sampled who were initially without antibody developed mumps antibody following vaccination, giving a seroconversion rate of 98%. The vaccinated children presented no evidence of fever or other untoward clinical reaction referable to the vaccine. It was concluded that the vaccine was safe, highly efficacious in stimulating the production of neutralizing antibody, and readily applicable to the routine pediatric clinic.

scholarly journals Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV)

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 470
Author(s):  
Mark Westman ◽  
Dennis Yang ◽  
Jennifer Green ◽  
Jacqueline Norris ◽  
Richard Malik ◽  
...  
Keyword(s):  
Antibody Response ◽  
Virus Vaccine ◽  
Point Of Care ◽  
Primary Vaccination ◽  
Antibody Responses ◽  
Blood Samples ◽  
Study Results ◽  
Elisa Testing ◽  
Primary Antibody Response ◽  
Residual Blood

Although the antibody response induced by primary vaccination with Fel-O-Vax® FIV (three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccination with Fel-O-Vax® FIV (single dose every 12 months after primary vaccination) and how it compares to the primary antibody response has not been studied. Residual blood samples from a primary FIV vaccination study (n = 11), and blood samples from cats given an annual FIV vaccination (n = 10), were utilized. Samples from all 21 cats were tested with a commercially available PCR assay (FIV RealPCRTM), an anti-p24 microsphere immunoassay (MIA), an anti-FIV transmembrane (TM; gp40) peptide ELISA, and a range of commercially available point-of-care (PoC) FIV antibody kits. PCR testing confirmed all 21 cats to be FIV-uninfected for the duration of this study. Results from MIA and ELISA testing showed that both vaccination regimes induced significant antibody responses against p24 and gp40, and both anti-p24 and anti-gp40 antibodies were variably present 12 months after FIV vaccination. The magnitude of the antibody response against both p24 and gp40 was significantly higher in the primary FIV vaccination group than in the annual FIV vaccination group. The differences in prime versus recall post-vaccinal antibody levels correlated with FIV PoC kit performance. Two FIV PoC kits that detect antibodies against gp40, namely Witness® and Anigen Rapid®, showed 100% specificity in cats recently administered an annual FIV vaccination, demonstrating that they can be used to accurately distinguish vaccination and infection in annually vaccinated cats. A third FIV PoC kit, SNAP® Combo, had 0% specificity in annually FIV-vaccinated cats, and should not be used in any cat with a possible history of FIV vaccination. This study outlines the antibody response to inactivated Fel-O-Vax® FIV whole-virus vaccine, and demonstrates how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced.

Jeryl Lynn Strain Live Attenuated Mumps Virus Vaccine

JAMA ◽  
1968 ◽  
Vol 203 (1) ◽  
pp. 14 ◽  
Author(s):  
Robert E. Weibel
Keyword(s):  
Virus Vaccine ◽  
Mumps Virus

scholarly journals Matched Case-Control Study of Effectiveness of Live, Attenuated S79 Mumps Virus Vaccine against Clinical Mumps

2008 ◽  
Vol 15 (9) ◽  
pp. 1425-1428 ◽  
Author(s):  
Chuanxi Fu ◽  
Jianhua Liang ◽  
Ming Wang
Keyword(s):  
Virus Vaccine ◽  
Case Control Study ◽  
Early Adulthood ◽  
Mumps Virus ◽  
Control And Prevention ◽  
Matched Case ◽  
Pediatric Use ◽  
Computerized System ◽  
Matched Case Control Study ◽  
Control Study

ABSTRACT Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live, attenuated S79 mumps virus vaccine has been licensed for pediatric use since 1990. There has been no assessment of its efficacy. Thus, the objective of this study was to determine the effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Cases were selected from the China Information System for Disease Control and Prevention during September 2004 to March 2005. Each case was matched to a control by gender, age, and area of residency. In all, 469 cases and 469 controls were enrolled in the study. Vaccination information was obtained from the Children's EPI Administrative Computerized System. Vaccine effectiveness (VE) was calculated for one or two doses of S79 vaccine, with 95% confidence intervals (CI). VE of mumps virus vaccine for one dose versus none was protection of 86.0% (95% CI, 77.2% to 91.5%) of recipients, and VE was much higher in the first 4 years than in the 5 to 12 years after vaccination. The S79 vaccine can effectively prevent clinical mumps, and a second dose of mumps virus vaccine is necessary for the protection of children in China.

Jeryl Lynn Strain Live Mumps Virus Vaccine

JAMA ◽  
1969 ◽  
Vol 207 (9) ◽  
pp. 1667 ◽  
Author(s):  
Robert E. Weibel
Keyword(s):  
Virus Vaccine ◽  
Mumps Virus

scholarly journals Immunomodulatory Activity and Phytochemical Profile of Infusions from Cleavers Herb

Molecules ◽  
2020 ◽  
Vol 25 (16) ◽  
pp. 3721 ◽  
Author(s):  
Tetiana Ilina ◽  
Weronika Skowrońska ◽  
Natalia Kashpur ◽  
Sebastian Granica ◽  
Agnieszka Bazylko ◽  
...  
Keyword(s):  
Skin Diseases ◽  
Herbal Remedy ◽  
Folk Medicine ◽  
Immunomodulatory Activity ◽  
Blast Transformation ◽  
Immunostimulatory Activity ◽  
Traditional Use ◽  
Aerial Parts ◽  
Lymphocyte Blast Transformation

Extracts from aerial parts of G. aparine (cleavers) constitute a herbal remedy with monography in British Herbal Pharmacopeia. On the European market, there are several drugs and food supplements consisting of Galium extracts. In folk medicine, cleavers was used topically in Europe, Asia, and the Americas to treat skin diseases. In several remedies, cleavers is also listed as an immunomodulatory active herb influencing the defense response of the human body. The aim of this study was to investigate the immunostimulatory activity and antioxidant potential in vitro of a raw infusion of cleavers and bioactive fractions. The functional activity of lymphocytes in the reaction of the lymphocyte blast transformation (RLBT) method was used for immunomodulatory activity assays and direct scavenging of 2,2-diphenyl-1-picrylhydrazyl (DPPH), nitric oxide (NO), and hydrogen peroxide (H2O2) was chosen for the examination of antioxidant activity. It was shown that both the raw extract and fractions show significant immunostimulatory and scavenging activities. The obtained data partially justify the traditional use of cleavers as topical remedy for skin infections and for wounds.

Sign in / Sign up

Export Citation Format

Share Document